FDA WARNING_LETTER - Monarch PCM, LLC - August 20, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspected Monarch PCM, LLC from June 7 to August 20, 2021, identifying significant Current Good Manufacturing Practice (CGMP) violations, rendering their drug products adulterated. The firm manufactures Hydroquinone USP, 4% Skin Bleaching Cream, Sodium Sulfacetamide 10% Wash, Sodium Sulfacetamide 10% and Sulfur 5% Cleanser, and Selenium Sulfide 2.25% Shampoo, which are cited as unapproved new drugs. Additionally, Hydroquinone USP 4% Skin Bleaching Cream and Selenium Sulfide 2.25% Shampoo are not properly listed with the FDA, making them misbranded.
Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** Failure to thoroughly investigate out-of-specification (OOS) results for drug components and finished products, including microbial contamination (Burkholderia cepacia complex - BCC). Investigations were insufficient, often invalidating OOS results based on retesting without scientific justification, and failing to implement adequate corrective and preventive actions (CAPAs). 2. **Inappropriate Equipment Design and Maintenance (21 CFR 211.63):** Water systems and manufacturing equipment are not designed, cleaned, or maintained appropriately, contributing to persistent objectionable microorganism findings. 3. **Quality Control Unit Failures (21 CFR 211.22):** The Quality Unit
ID · 4c4d52f4-8239-48e7-b083-cca2959d1604
Full citation text and observation details available on the Dashboard.